Long-term arsenic exposure is associated with an increased risk of vascular diseases including ischemic heart disease, cerebrovascular disease, and carotid atherosclerosis. The pathogenic mechanisms of arsenic atherogeneity are not completely clear. A fundamental role for inflammation in atherosclerosis and its complications has become appreciated recently. To investigate molecular targets of inflammatory pathway possibly involved in arsenic-associated atherosclerosis, we conducted an exploratory study using cDNA microarray and enzyme-linked immunosorbent assay to identify genes with differential expression in arsenic-exposed yet apparently healthy individuals. As an initial experiment, array hybridization was performed with mRNA isolated from activated lymphocytes of 24 study subjects with low (0–4.32 µg/L), intermediate (4.64–9.00 µg/L), and high (9.60–46.5 µg/L) levels of blood arsenic, with each group comprising eight age-, sex-, and smoking frequency-matched individuals. A total of 708 transcripts of known human genes were analyzed, and 62 transcripts (8.8%) showed significant differences in the intermediate or high-arsenic groups compared with the low-level arsenic group. Among the significantly altered genes, several cytokines and growth factors involving inflammation, including interleukin-1 beta, interleukin-6, chemokine C-C motif ligand 2/monocyte chemotactic protein-1 (CCL2/MCP1), chemokine C-X-C motif ligand 1/growth-related oncogene alpha, chemokine C-X-C motif ligand 2/growth-related oncogene beta, CD14 antigen, and matrix metalloproteinase 1 (interstitial collagenase) were upregulated in persons with increased arsenic exposure. Multivariate analyses on 64 study subjects of varying arsenic exposure levels showed that the association of CCL2/MCP1 plasma protein level with blood arsenic remained significant after adjustment for other risk factors of cardiovascular diseases. The results of this gene expression study indicate that the expression of inflammatory molecules may be increased in human subjects after prolonged exposure to arsenic, which might be a contributory factor to the high risk of atherosclerosis in arseniasis-endemic areas in Taiwan. Further multidisciplinary studies, including molecular epidemiologic investigations, are needed to elucidate the role of arsenic-associated inflammation in the development of atherosclerosis and subsequent cardiovascular disease. Key words: arsenic exposure, atherosclerosis, gene expression, inflammation. Environ Health Perspect 111:1429–1438 (2003). doi:10.1289/txg.6396 available via http://dx.doi.org/[Online 23 July 2003]
expressed genes in peripheral blood lymphocytes (PBLs) from arsenic-exposed individuals. Recent studies in microarray analysis concerning adverse health effects of arsenic have been focused mainly on its carcinogenic properties (Chen et al. 2001; Lu et al. 2001; Yih et al. 2002). Few gene expression studies have focused on the atherogenic effect of arsenic exposure. In this report, we first demonstrated the application of cDNA microarray technology to identify gene expression changes in PBLs from arsenic-exposed individuals and show that blood arsenic is significantly associated with changes in transcription levels of several inflammatory mediator genes that have been implicated in the atherosclerotic process. PBLs do not represent all the cells involved in progression of atheroma formation but are the only collectable cell samples from apparently healthy humans in a population study, which may reflect the inflammatory response to an environmental injury. The enhanced expression of inflammatory molecules in blood leukocytes from an arsenic-exposed population may contribute to the development of atherosclerosis associated with arsenic exposure.

Materials and Methods

Study Subjects and Tissue Samples

Sixty-four residents identified as consumers of arsenic-tainted well water in Lanyang Basin of northeastern Taiwan, Republic of China, were recruited for previous studies of arsenic toxicity (Wu et al. 2001). For the present study, frozen peripheral blood lymphocytes and plasma samples previously stored from the study subjects were analyzed. Detailed characteristics of the study area, subject recruitment and blood collection, and determination of arsenic concentration in whole blood samples have been described previously (Wu et al. 2001). Isolation, freezing, and storage of the lymphocytes in liquid nitrogen were performed according to the methods described by Venkataraman and Westerman (Venkataraman and Westerman 1986). Plasma samples were preserved at −20°C until protein assay was performed for this study. Computerized records of the serum levels of total cholesterol and triglycerides initially determined by an autoanalyzer were retrieved for the study subjects. Information on demographic or clinical characteristics, as well as lifestyle data including alcohol consumption and smoking habits of the study subjects were also obtained from previous records. All study subjects gave their consent and were free of clinical symptoms, as described in our previous study using the same population (Wu et al. 2001).

mRNA Preparation and cDNA Microarray Analysis

Because of limited samples of frozen lymphocytes, only the study subjects who had a cell number of 15–20 × 10^6 in stock were selected for the cDNA microarray hybridization analysis as an initial experiment. A total of 24 study subjects whose cells were available from the archives were further separated into groups on the basis of blood arsenic levels [low (0.00–4.32 µg/L), intermediate (4.64–9.00 µg/L) and high (9.60–46.5 µg/L)], with each group comprising eight similar age-, sex-, and smoking-frequency–matched individuals. Lymphocyte samples were thawed and cultured in RPMI-1640 medium (GIBCO, Grand Island, NY, USA) supplemented with 20% heat-inactivated fetal bovine serum (Hyclone Laboratory, Logan, UT, USA), 100 U/mL penicillin, and 100 µg/mL streptomycin at 37°C in a humidified atmosphere containing 5% CO₂ for 68 hr. Using TRI reagent (Molecular Research Center, Cincinnati, OH, USA), we extracted a total of 30–50 µg cellular RNA from the harvested cells for each study subject, which was further pooled into groups of low, intermediate, or high arsenic levels for subsequent isolation of mRNA. mRNA was extracted using Oligotex-dT resin (Qiagen, Hilden, Germany) and was used to prepare targets for cDNA microarray hybridization and first-strand cDNA for quantitative real-time polymerase chain reaction (PCR) assay.

Seven hundred eight cDNA elements used as probes, including 662 known genes of potential significance in arsenic toxicity, 16 housekeeping genes, and 22 expressed-sequence tags (ESTs), were prepared by PCR amplification of IMAGE consortium cDNA clones and arrayed on a 5 × 8 mm nylon membrane, using methods described previously (Chen et al. 1998). Also included in the membrane chip were eight plant genes, whose hybridization results served as negative controls. The cDNA microarray hybridization experiment was performed with this 708 cDNA probes array using a colorimetric detection method described previously (Yih et al. 2002). Briefly, biotin-labeled cDNA targets were prepared from 2 µg mRNA by reverse transcriptase (Superscript II; GIBCO BRL, Gaithersburg, MD, USA) incorporation of biotin-16–2-deoxyuridine-5′-triphosphate (Roche Diagnostics, Mannheim, Germany). After precipitation, the labeled targets were dissolved in hybridization buffer and incubated with the prehybridization-treated probes array at 65°C overnight. The hybridized arrays were then washed at room temperature twice in 2 × SSC (0.15 M NaCl/0.015 M Na citrate, pH 7.0), 0.1% sodium dodecyl sulfate (SDS) for 5 min, and 3 times at 65°C in 0.1 × SSC, 0.1% SDS for 15 min. After thorough washing, the arrays were blocked and incubated with streptavidin–β-galactosidase conjugate reagent for chromagen development. After a wash to remove any unbound conjugates, an X-gal substrate solution was added to the array and incubated at 37°C for 30 min with occasional shaking. Color development was terminated by addition of phosphate-buffered saline. The signal intensity of spots on arrays was acquired using a flatbed scanner at appropriate optical resolution. Quantitative results were analyzed using GenePix Pro (version 3.0; Axon Instruments, Union, CA, USA) and Microsoft Excel 2000 software (version 9; Microsoft Corp., Taipei, Taiwan).

To allow for better comparison between hybridization experiments, a series of four array probes was prepared for each membrane using known concentrations of 10-fold serial dilutions of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) clone. A standard curve plotting the signal intensity versus the concentration of four serial-diluted GAPDH clones was generated for each set of gene spots to be tested on one array. By comparing the signal intensity of the tested spot to this standard curve, the relative intensity of the spot was normalized against GAPDH intensity. After standardization, ratios of relative intensity were calculated between arsenic groups for all gene spots. Genespecific signal ratio was considered significant if the logarithm of the ratio differed by ± 3 SD from the mean log of the ratio for the housekeeping genes set. To date, arsenic has not been shown to have appreciable effects on the expression of these housekeeping genes.

Quantitative Reverse-Transcriptase–Polymerase Chain Reaction Analysis

The quantitation of mRNA level was carried out using a real-time SYBER Green I fluorescence detection method as described previously (Morrison et al. 1998; Wittwer et al. 1997). In brief, 1 µg mRNA was first reverse-transcribed into cDNA using random primers (Roche Diagnostic) and purified by a 30-min incubation at 37°C with RNase H (Invitrogen, Carlsbad, CA, USA) followed by ethanol precipitation. The specific cDNA of interest and a reference cDNA, GAPDH, were PCR-amplified separately in optical tubes and caps using the ABI PRISM 7700 sequence detection system (Applied Biosystems, Foster, CA, USA). Primer design and PCR reaction were performed according to commercial
instructions provided by Applied Biosystems. Dissociation curve analysis was performed after PCR amplification (ABI PRISM 7700; Applied Biosystems) to ensure no fluorescence contamination from nonspecific dsDNA product. Results of the derivative dissociation curve profile exhibited no nonspecific products in PCR reaction solution. All PCR reactions were performed in duplicate.

Initial template concentration of a specific gene was derived from the cycle number at which the fluorescent signal crossed a threshold in the exponential phase of the PCR reaction. For comparison of mRNA levels between groups, relative gene expression level was first determined by subtracting from the respective cycle number of GAPDH gene for each group. Values were then used to calculate for relative folds normalized to the relative amounts of the same gene in the low-level arsenic group.

**Enzyme-linked immunosorbent assay.**

Selected inflammatory molecules, including interleukin-1 beta (IL1β), interleukin-6 (IL6), chemokine C-C motif ligand 2/monocyte chemotactic protein-1 (CCL2/MCP1), and chemokine C-X-C motif ligand 1/growth-related oncogene alpha (CXCL1/GRO1) protein levels in plasma, were measured for the 64 study subjects by enzyme-linked immunosorbent assay (ELISA; Biotrak, Piscataway, NJ, USA) according to the manufacturer’s instructions. Lower limits of detection of assays for IL1β, IL6, CCL2/MCP1, and CXCL1/GRO1 were 0.31, 0.31, 20.5, and 15.6 pg/mL, respectively.

**Statistical Methods**

For comparison of more than two groups, one-way analysis of variance (ANOVA) or chi-square test was applied where appropriate. Spearman correlation coefficient was used to determine statistical association between study variables. We performed multiple linear regression analysis to examine the effect of arsenic concentration on the protein expression level in plasma after controlling for confounding factors. Statistical significance was accepted at a level of $p < 0.05$.

**Results**

**Differentially Expressed Genes in Lymphocytes of Arsenic-Exposed Individuals**

To identify genes potentially associated with arsenic atherogenicity, we compared the gene expression profile of peripheral blood lymphocytes from 24 selected individuals of low-, intermediate-, or high-level arsenic exposure groups (Figure 1; detailed information on the 708 cDNA clones spotted on membrane chip, as well as the resultant signal intensity for each study gene, are accessible at http://www.ibms.sinica.edu.tw/~bmtcl/As-chip-TCL01-PBL.xls). Hybridization intensities of the four serially diluted GAPDH clones are shown on the eighth line from the top. The GAPDH transcription levels showed a logarithmic relation with signal intensity, and a standard curve for linear transformation was generated as described in "Materials and Methods." Table 1 includes the relative intensities of nine housekeeping genes among groups of varying arsenic exposure; the other seven housekeeping genes were either duplicates or had an expression level.

---

**Table 1.** Relative intensity of mRNA levels of nine housekeeping genes in peripheral blood lymphocytes from arsenic-exposed study subjects, Lanyang Basin, Taiwan.a,b

| Accession number | Description | Low (0.00–4.32) | Intermediate (4.64–9.00) | High (9.60–46.5) | Log$_2$ (Intermediate/low) | Log$_2$ (High/low) | Log$_2$ (High/intermediate) |
|------------------|-------------|----------------|--------------------------|-----------------|-----------------------------|-------------------|-----------------------------|
| AA186639         | Ribosomal protein S27 | 1313.14 | 1414.26 | 1085.65 | 0.107 | –0.274 | –0.381 |
| AA126291         | H3 histone, family 3B | 1314.83 | 1103.04 | 1204.01 | –0.253 | –0.127 | 0.126 |
| AA053244         | Basic transcription factor 3 | 152.35 | 85.07 | 106.88 | –0.841 | –0.511 | 0.329 |
| AA065001         | Ribosomal protein S3 | 1510.32 | 1327.67 | 1172.98 | –0.186 | –0.385 | 0.179 |
| AA147674         | Ribosomal protein S20 | 936.38 | 921.45 | 890.70 | 0.023 | 0.072 | 0.049 |
| AA064618         | Ribosomal protein L28 | 1510.32 | 1327.67 | 1172.98 | –0.186 | –0.385 | 0.179 |
| AA131097         | Ribosomal protein S5 | 407.75 | 320.50 | 426.96 | –0.347 | –0.066 | 0.414 |
| M33197           | GAPDH, 1:10 dilution | 1313.14 | 1414.26 | 1085.65 | 0.107 | –0.274 | –0.381 |
| H66115           | Glucose phosphate isomerase | 152.35 | 85.07 | 106.88 | –0.841 | –0.511 | 0.329 |

---

*a* mRNA was extracted from pooled total RNA samples obtained from 8 individuals representative of each arsenic group. The eight individuals were age-, sex-, and smoking-frequency-matched among groups. *b* Quantification of each individual gene in one group was standardized to a calibration curve established from serial dilutions of GAPDH gene of the same group.

---

*Environmental Health Perspectives • VOLUME 111 | NUMBER 11 | August 2003*
below threshold. As demonstrated in Table 1, housekeeping genes showed relatively constant expression levels among groups; the means of the logarithm base 2 of signal ratio (± SD) were –0.190 (± 0.322), –0.178 (± 0.217), and 0.012 (± 0.344) for intermediate versus low, high versus low, and high versus intermediate, respectively. On the basis of the expression variation with 3 × SD from the mean log for the housekeeping genes, we identified 26 cDNA clones with an increased expression signal in intermediate- or high-level arsenic groups, and 36 cDNA clones with reduced expression in intermediate- or high-level arsenic groups compared with the low-level arsenic group. Except for five clones of EST or clones withdrawn from the Unigene database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene), the remaining 57 genes of known function included those involving growth factor or cytokine related, signaling transduction pathway, transcription regulatory components, cell-cycle control, DNA replication/repair activity, redox homeostasis, and matrix-degrading enzymes (Table 2).

Of particular interest, genes of cytokine-related or growth factors involving inflammation were significantly elevated in the high-level arsenic exposure groups (Table 2). These inflammatory molecules have recently been implicated in the atherosclerotic process for a variety of vascular diseases. A number of these genes detected by the microarray as significantly induced in lymphocytes, such as IL1β, IL6, CCL2/MCP1, CXCL1/GRO1, chemokine C-X-C motif ligand 2/growth-related oncogene beta (CCL2/GRO2), CD14 antigen (CD14), and interstitial collagenase matrix metalloproteinase 1 (MMP1), were selected for a confirmation test using a real-time reverse-transcriptase–polymerase chain reaction method. As indicated in Figure 2, we reconfirmed the change profile in gene expression of these genes in parallel with the arsenic exposure group. Comparison of the colorimetric cDNA microarray method with SYBR Green I real-time PCR assay (Applied Biosystems) showed consistent fold changes in expression for these six genes.

Protein Levels of Inflammatory Molecules in Plasma of Arsenic-Exposed Individuals

Four genes detected by the microarray as significantly induced in PBL of the higher-level arsenic groups, including IL1β, IL6, CCL2/MCP1, and CXCL1/GRO1, were studied by ELISA assay to quantitatively evaluate protein expression level in plasma samples of 64 study subjects. Demographic and clinical characteristics of the study subjects by blood arsenic concentration are summarized in Table 3. As shown in this table, the three groups of varying arsenic exposure did not differ with respect to age, percentage of male gender, current smoker, serum cholesterol, or triglyceride but differed in regard to body mass index. Study subjects of high-level arsenic group were significantly overweight as compared with the other two groups (p = 0.021).

Table 4 shows the results of ELISA assay for IL1β, IL6, CCL2/MCP1, and CXCL1/GRO1 protein expression level in plasma of the study subjects. Although there was considerable variation within each arsenic group, a positive correlation was observed between arsenic exposures and plasma protein levels of CCL2/MCP1. Because the distribution of plasma protein levels in these study subjects was wide and skewed to the left, individual measurements of protein level were logarithmically transformed in the next regression analysis for CCL2/MCP1 to reduce the influence of extreme values on the estimates of parameters. As summarized in Table 5, we found no significant association of plasma CCL2/MCP1 protein level with body mass index, cholesterol, triglyceride, or smoking status. However, blood arsenic concentration was significantly associated with the CCL2/MCP1 protein level after adjustment for age and gender through multivariate regression analysis.

Discussion

Arsenic is an environmental contaminant that warrants high concern for human health. Long-term arsenic exposure is closely associated with adverse health effects, including several vascular disorders (Chen et al. 1996; Chiou et al. 1997; Engel et al. 1994; Tseng et al. 1995, 1996; Wang et al. 2002). The possibility that arsenic induces atherosclerosis through its actions on the change of inflammatory-related gene expression needs to be elucidated. By using cDNA microarray analysis on circulating lymphocytes from healthy arsenic-exposed individuals, we found that alteration in expression level of several genes involved in inflammation showed a positive correlation with arsenic concentration in the whole blood of study subjects. In some of study genes, a dose–response relationship between transcription level and arsenic exposure was not observed; in this case, there might be other risk factors interfering with gene expression, thus confounding the dose-dependent pattern under study in this population. As individual RNA samples were not available, the influence of a potential confounding effect was not examined. However, further studies of plasma protein level by ELISA exhibited a significant correlation with CCL2/MCP1 that remained significant after adjustment for other risk factors of cardiovascular disease. In contrast, we found no significant correlation of plasma protein levels for IL1β, IL6, and CXCL1/GRO1 with blood arsenic as observed in the gene expression studies. It is probable that because of posttranscriptional regulation, changes in mRNA expression would not show corresponding changes in protein levels. In addition, the number of study subjects for these genes may not be large enough to draw a definite conclusion on the association between plasma protein level and arsenic exposure gradient. Taken together, the enhanced expression of the inflammatory molecules observed in blood lymphocytes of arsenic-exposed study subjects may contribute to the atherosclerotic process caused by arsenic, although other gene factors cannot be excluded.

The role of inflammatory cytokines or growth factors with inflammatory reactivity has gained increasing attention in the pathogenesis of atherosclerotic lesions (Libby et al. 2002; Ross 1999). The main contributors to the risk for atherosclerosis include lipoprotein, homocysteine, hypertension, diabetes, infectious agents, and oxidant stress (Libby et al. 2002). Arsenic is widely accepted as a prooxidant stimulus. In humans, prolonged exposure to arsenic that accompanies persistent oxidative stress in the vasculature system might trigger inflammation and thereafter lead to atheroma formation. Although directed migration of mononuclear leukocytes, including T lymphocytes, into the tunica intima by chemokines produced by endothelial and smooth muscle cells characterizes the initiation of the atherosclerotic lesions, the activated leukocytes in arterial intima also secrete proinflammatory cytokines that amplify inflammatory response in the lesion (Libby 2002). How the induction of inflammatory mediators in activated T lymphocytes residing in blood circulation or in arterial intima of arsenic-exposed humans might lead to atherosclerosis requires further study. In the present study, gene expression of IL1β and IL6 was elevated in association with arsenic exposure in the study subjects. IL1β contributes to vascular smooth muscle cell (VSMC) proliferation and lesion progression in atherosclerosis (Nathe et al. 2002). IL6 plays a role in atherosclerosis as a mediator in chemotactic activity or in cell proliferation after stress stimuli (Klouche et al. 2000; Verma et al. 2002). CCL2/MCP1 is a key mediator of leukocyte transmigration.
### Table 2. Relative intensity of mRNA levels of differentially expressed genes in peripheral blood lymphocytes from arsenic-exposed study subjects, Lanyang Basin, Taiwan.  

| Accession number | Description; symbol | Low (0.00–4.32) | Intermediate (4.64–9.00) | High (9.60–46.5) | log2 (High/intermediate) | log2 (Intermediate/low) | Log2 (High/low) | Arsenic concentration in blood (µg/L) |
|------------------|----------------------|------------------|--------------------------|------------------|--------------------------|-------------------------|------------------|-------------------------------|
| **Growth factor or cytokine-related genes** | | | | | | | | | |
| AA150507 | Interleukin-1, beta; IL1B | 65.12 | 86.98 | 137.97 | 0.416 | 1.082 | 0.666 | |
| N09851 | Interleukin-6 (interferon, beta 2); IL6 | 50.95 | 48.54 | 131.15 | -0.070 | 1.364 | 1.434 | |
| H96871 | Chemokine (C-X-C motif) ligand 2; CCL2 | 36.09 | 113.89 | 105.92 | 1.658 | 1.553 | -0.105 | |
| W42737 | Chemokine (C-X-C motif) ligand 1; CXCL1 | 19.43 | 22.22 | 56.43 | 0.194 | 1.538 | 1.344 | |
| AA487453 | Chemokine (C-X-C motif) ligand 2; CCL2 | 80.61 | 85.57 | 202.63 | 0.086 | 1.330 | 1.244 | |
| R94179 | Hepatoma-derived growth factor (high-mobility group protein 1-like); HDGF | 76.53 | 63.92 | 115.21 | -0.260 | 0.590 | 0.850 | |
| H11719 | CD14 antigen; CD14 | 6.76 | 9.70 | 14.48 | 0.522 | 1.100 | 0.577 | |
| H57126 | Colony-stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (v-fms) oncogene homolog; CSF1R | 3.29 | 3.80 | 4.83 | 0.207 | 0.667 | 0.346 | |
| **Signal transduction pathway genes** | | | | | | | | | |
| H11455 | RAS, member RAS oncogene family; RAB5A | 81.97 | 34.13 | 50.71 | -1.264 | -0.693 | 0.571 | |
| R20665 | Endothelial differentiation, sphingolipid G-protein-coupled receptor, 1; EDG1 | 208.10 | 92.21 | 134.84 | -1.174 | -0.626 | 0.548 | |
| R43007 | Annexin A7; ANXA7 | 336.47 | 246.85 | 183.48 | -0.447 | -0.875 | -0.429 | |
| R84980 | Inositol 1,3,4-triphosphate 5/6 kinase; ITPK1 | 22.22 | 22.32 | 34.76 | 0.045 | 0.646 | 0.691 | |
| N62226 | Phosphatidylinositol 4-kinase, catalytic, alpha polypeptide, PKC4A | 42.87 | 46.04 | 74.82 | 0.103 | 0.804 | 0.701 | |
| R39925 | Phosphoinositide-3-kinase, regulatory subunit, polypeptide 1 (p85 alpha); PK3R1 | 35.74 | 18.15 | 17.53 | -0.978 | -1.027 | -0.049 | |
| R42845 | Myotubular myopathy 1; MTPM1 | 19.61 | 9.95 | 10.39 | -0.979 | -0.916 | 0.064 | |
| H07920 | Mitogen-activated protein kinase kinase 6; MAPK6 | 11.58 | 7.49 | 4.69 | -0.630 | -1.304 | -0.674 | |
| T85100 | Mitogen-activated protein kinase 6; MAPK6 | 196.18 | 62.01 | 80.79 | -1.862 | -1.144 | 0.510 | |
| T5875 | Protein kinase C, iota; PKC1I | 58.04 | 24.14 | 42.34 | -1.266 | -0.455 | 0.811 | |
| R43147 | Protein kinase, cAMP-dependent, regulatory, type1, alpha (tissue-specific extinguisher 1); PRKAR1A | 357.86 | 156.01 | 187.91 | -1.198 | -0.929 | 0.268 | |
| AA018676 | Protein kinase, AMP-activated, gamma 1 noncatalytic subunit; PRKAG1 | 260.15 | 152.28 | 142.57 | -0.773 | -0.889 | -0.095 | |
| **Transcription regulatory genes** | | | | | | | | | |
| R08580 | Spleen focus forming virus (SFV) proviral integration oncogene sp1; SPY1 | 27.18 | 32.21 | 40.65 | 0.245 | 0.581 | 0.336 | |
| R15253 | V-fos FBJ murine osteosarcoma viral oncogene homolog; FOS | 136.24 | 126.03 | 63.85 | -0.112 | -1.093 | -0.981 | |
| H24055 | Heat-shock transcription factor 2; HSFC2 | 575.88 | 357.86 | 301.82 | -0.688 | -0.932 | -0.246 | |
| H07034 | B-cell CLL/lymphoma 6 (zinc finger protein 51); BCL6 | 20.58 | 10.22 | 10.06 | -0.983 | -1.033 | -0.050 | |
| R39723 | MAD, mothers against decapentaplegic homolog 4 (Drosophila; MADH4) | 94.47 | 38.76 | 59.69 | -1.285 | -0.662 | 0.623 | |
| H18461 | Transcription factor A, mitochondrial; TFAM | 100.56 | 41.70 | 56.65 | -1.270 | -0.828 | 0.442 | |
| H96354 | AKT oncogene (DNA binding), AKT | 59.54 | 30.49 | 30.07 | -0.965 | -0.986 | -0.020 | |
| H22977 | General transcription factor IIB, GTF2B | 137.75 | 72.43 | 69.72 | -0.927 | -0.962 | -0.055 | |
| R91548 | Topoisomerase (DNA I); TOP1 | 194.36 | 85.65 | 150.14 | -1.182 | -0.298 | 0.894 | |
| T65211 | SFRS protein kinase 2; SRFK2 | 50.82 | 19.55 | 27.73 | -1.378 | -0.874 | 0.504 | |
| R55052 | PR54 pre-mRNA processing factor 4 homolog B (yeast); PRPF4B | 156.81 | 89.06 | 84.36 | -0.816 | -0.894 | -0.078 | |
| **Cell-cycle control genes** | | | | | | | | | |
| N21348 | Menage a trois 1 (CAK assembly factor); MNAT1 | 3.29 | 2.90 | 6.16 | -0.185 | 0.903 | 1.088 | |
| AA164211 | Cyclin G, CCNG | 219.44 | 91.80 | 150.92 | -1.257 | -0.540 | 0.717 | |

Continued, next page
Table 2. Continued.

| Accession number | Description; symbol | Low (0.00–4.32) | Intermediate (4.64–9.00) | High (9.60–46.5) | Arsenic concentration in blood (µg/L) |
|------------------|---------------------|-----------------|--------------------------|-----------------|--------------------------------------|
|                  |                     |                 |                          |                 | log₂ (Intermediate/low) | log₂ (High/low) | log₂ (High/intermediate) |
| DNA replication/repair genes |                     |                 |                          |                 |                       |                  |                           |
| AA028094         | Poly(A) polymerase (DNA directed), delta 2, 80kDa; POLB | 144.11          | 141.44                   | 229.63          | −0.027                 | 0.672d           | 0.699               |
| H14431           | Poly(A) polymerase (DNA directed), beta; POLB          | 32.88           | 16.48                    | 18.06           | −0.997                 | −0.864e          | 0.132               |
| AA035956         | Excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence); ERCC1 | 34.26           | 22.21                    | 49.96           | −0.625                 | 0.544d           | 1.170d              |
| AA013051         | Topoisomerase (DNA) II binding protein; TOPBP1 | 193.73          | 78.51                    | 142.76          | −1.303e                | −0.440           | 0.863               |
| Redox homeostasis genes |                     |                 |                          |                 |                       |                  |                           |
| R81700           | Glutathione peroxidase 4 (phospholipid hydroperoxidase); GPX4 | 24.12           | 16.35                    | 34.27           | −0.561                 | 0.507d           | 1.068d              |
| NM_002133        | Heme oxygenase (decycling) 1; HMOX1 | 19.83           | 27.96                    | 39.38           | 0.496                  | 0.990d           | 0.494               |
| R45064           | Serine/threonine kinase 38 | 70.88           | 30.52                    | 43.83           | −1.216e                | −0.693           | 0.522               |
| T77613           | Aldehyde dehydrogenase 3 family, member A2; ALOX4Z2 | 23.39           | 10.83                    | 12.83           | −1.111                 | −0.866e          | 0.244               |
| R49679           | CXCL1 homolog, cytokine c oxidase assembly protein (yeast); CXOX1 | 23.79           | 14.02                    | 11.75           | −0.763                 | −1.018e          | −0.255              |
| Matrix-degrading enzymes |                     |                 |                          |                 |                       |                  |                           |
| AA081006         | Matrix metalloproteinase 1 (interstitial collagenase); MMP1 | 3.29            | 3.68                     | 6.47            | 0.161                  | 0.973d           | 0.812               |
| R68367           | Matrix metalloproteinase 12 (macrophage elastase); MMP12 | 4.37            | 5.65                     | 6.14            | 0.371                  | 0.490d           | 0.119               |
| N32214           | Matrix metalloproteinase 14 (membrane-inserted); MMP14 | 8.91            | 12.10                    | 18.38           | 0.442                  | 1.044d           | 0.603               |
| R58652           | Matrix metalloproteinase 19; MMP19 | 3.29            | 3.65                     | 4.74            | 0.150                  | 0.525d           | 0.375               |
| Miscellaneous genes |                     |                 |                          |                 |                       |                  |                           |
| AA134959         | Interferon-induced protein with tetratricopeptide repeats 4; IFIT4 | 25.97           | 28.95                    | 37.84           | 0.157                  | 0.543d           | 0.386               |
| R32850           | Major histocompatibility complex, class I, E; HLA-E | 13.74           | 13.08                    | 20.42           | −0.071                 | 0.572d           | 0.643               |
| AA031807         | Feline sarcoma oncoprotein; FES | 9.40            | 6.98                     | 14.28           | −0.430                 | 0.602d           | 1.032               |
| AA031530         | Brain protein 13; BR13 | 3.64            | 3.53                     | 5.28            | −0.044                 | 0.537d           | 0.501               |
| R94976           | PTD009 protein; PTD009 | 4.06            | 3.35                     | 5.85            | −0.275                 | 0.529d           | 0.804               |
| AA515390         | Lamin B receptor; LBR | 208.98          | 88.26                    | 172.33          | −1.244e                | −0.278           | 0.965               |
| R41478           | COP9 homolog; COP9 | 75.55           | 40.58                    | 41.11           | −0.897                 | −0.878e          | 0.018               |
| H15248           | Lipase A, lysosomal acid, cholesterol esterase (Wolman disease); LIPA | 113.71          | 54.16                    | 41.92           | −1.070                 | −1.439e          | −0.369              |

*mRNA was extracted from pooled total RNA samples obtained from eight individuals representative of each arsenic group. The eight individuals were age-, sex-, and smoking-frequency–matched among groups. *Quantification of each individual gene in one group was standardized to a calibration curve established from serial dilutions of GAPDH gene of the same group. *Information from the UniGene database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene). *Significantly upregulated, defined as the log₂ of signal ratio (intermediate–low arsenic group, high–to-low arsenic group, or high to intermediate-level arsenic group) differs by ≥3 SD from the corresponding mean log₂ of the ratio for the nine housekeeping genes shown in the table. *Significantly downregulated, defined as the log₂ of signal ratio (intermediate to low-level arsenic group, high–to-low level arsenic group, or high–to-intermediate-level arsenic group) differs by ≤3 SD from the corresponding mean log₂ of the ratio for the nine housekeeping genes as shown in the table.

Figure 2. Relative abundance of mRNA level of IL1β, IL6, CCL2/MCP1, CXCL1/GRO1, CXCL2/GRO2, CD14, and MMP1 in peripheral blood lymphocytes of study subjects by arsenic exposure group. mRNA was extracted from pooled total RNA samples obtained from eight individuals representative of each arsenic group. The eight individuals were age, sex, and smoking-frequency matched among groups. (A) Genes obtained using a colorimetric cDNA microarray method. (B) Genes obtained by SYBR Green I real-time PCR assay. Sequences of primers used for PCR analysis were as follows. IL1β: (F)-AGCAGAAAACATGCCGCTTCTT, (R)-CCACATTGGCAACAGAGGACTCTTCTT, IL6: (F)-TGCTGACGACATGCAAA, (R)-TGAGTGCCCATGCACTATTCT, CCL2/MCP1: (F)-CCGAAATCTGACGGTACTATTT, (R)-AAGCGATATGGTCTCATCACAACACCGLR01: (F)-TTCGGAAGGCGCTCACAAGA, (R)-TTCCGGTCCTCCTCAGAATTG, CXCL2/GRO2: (F)-AGAGGCTAGAGAATCCGAAAGGAA, (R)-TGGAGAATGGTGGACACACAGCTGT, CD14: (F)-AGGAGCTGCCGACGAGGTCT, (R)-TTCCGGTCCTCCTCAGAATTG, MMP1: (F)-GCAGTTCAGTACAAACATATCC, (R)-GGTGACACGACTGACACCAACT, GAPDH: (F)-GGATGCTCCCTGACAATCTA, (R)-GCCCTCCCTCTTCAAG.
to sites of inflammation and thus plays an important role in the development of atherosclerosis (Rosenfeld 2002). Enhanced CCL2/MCP1 transcription level was also detected in lymphocytes from high arsenic level group in this study. Growth-stimulating gene expression, such as CXCL1/GRO1 and CXCL2/GRO2, was upregulated in the high-level arsenic exposure group. In experimental animals, CXCL1/GRO1 protein also triggers monocyte arrest on early atherosclerotic endothelium (Huo et al. 2001). CXCL2/GRO2 is a potent chemotactic agent for polymorphonuclear leukocytes as well (Wolpe et al. 1989). Hepatoma-derived growth factor (HDGF) was activated in study subjects of the high-level arsenic exposure group. Recent studies provide evidence for HDGF stimulation of DNA synthesis in VSMCs (Everett et al. 2001). CD14 molecules interact with apoptotic cells, triggering phagocytosis of the cells and also acting as a receptor that binds bacterial lipopolysaccharide, triggering inflammatory responses (Devitt et al. 1998). Colony-stimulating factor 1 receptor (CSF1R) encodes the receptor for macrophage colony-stimulating factor, potentially involved in promoting transforming activity (Hampe et al. 1989). Enhanced gene expression of both these genes was observed in subjects from the high-level arsenic exposure group in the present study. In contrast, mRNA levels of interferon gamma receptor 1 (IFNGR1), activin A receptor, type 1 (ACVR1), and activated leukocyte cell adhesion molecule (ALCAM) all exhibited downregulation in study subjects of the high-level arsenic exposure group. Repression of IFNGR1 was unexpected, as major histocompatibility complex, class I, E (HLA-E) was activated in association with high arsenic levels in the study subjects. Enhanced expression of both immune-related genes should have increased the overall inflammatory response. Downregulation of ACVR1 for activin may result in loss of induction for smooth muscle cell differentiation, and thus is involved in plaque destabilization (Engelse et al. 1999). ALCAM is a CD6 ligand expressed by activated leukocytes and involved in dynamic growth and/or migration (Swart 2002).

Abrupt expression of inflammatory cytokines or growth factors has been consistently noted in both in vitro or in vivo arsenic studies, although patterns of production vary between cell systems (Chen et al. 2001; Germolec et al. 1997, 1998; Lu et al. 2001; Yih et al. 2002). In cultured human keratinocytes or the Tg.Ac transgenic mouse model, sodium arsenite induced a dose-dependent increase in the expression of growth factors, including granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, or tumor growth factor-alpha, but not in the expression of inflammatory cytokines such as IL1β, IL6, or CCL2/MCP1 (Germolec et al. 1997, 1998). Altered expression in these growth factors is associated with the development of skin neoplasia (Germolec et al. 1997, 1998). Expression of IL6, CCL2/MCP1, CXCL1/GRO1, and CXCL2/GRO2 is decreased in human fibroblast cells after treatment with 5 µM arsenite for 0–24 hr (Yih et al. 2002). Results of another study, however, showed an enhanced expression of inflammatory cytokines or cytokine-related components, such as IL1 receptor and IL6 receptor, in arsenic-transformed cells associated with malignant transformation (Chen et al. 2001). In arsenic-exposed human livers, expression of hepatocyte growth factors IL1β, and IL6 receptor is also increased (Lu et al. 2001). In our study, increased gene expression of IL1β, IL6, CCL2/MCP1, CXCL1/GRO1, CXCL2/ GRO2, and HDGF as detected by cDNA microarray was observed in association with blood arsenic in activated lymphocytes of study subjects who had ingested arsenic-tainted well water for an extended period of time. The specific profile change of inflammatory molecules in leukocytes of the vasculature system identified in this study may differ from that found in previous studies using different cell systems; these studies usually focused on tumor development or high-dose treatments of arsenic. Recently, in cultured VSMCs we also found elevated expression of IL6 and CCL2/MCP1 genes in a dose-dependent manner after 0–5 µM arsenite treatment (Lee PC and Lee TC. Unpublished data). Atherosclerotic lesions have shown proliferation of smooth muscle cells involving activation and proliferation of macrophages and T lymphocytes, cytokine production, and oxidized low-density lipoprotein accumulation (Ross 1999). Studies have indicated that cholesterol and lipid uptake are unimportant factors for ischemic heart disease or peripheral vascular disease in arsengenic-hyperendemic areas in Taiwan (Chen et al. 1996; Hsueh et al. 1998; Tseng et al. 1997). Arsenic-induced inflammatory reaction has a potential contribution to the atherogenic effect of arsenic, possibly derived from a coordinated involvement of leukocyte recruitment and smooth muscle cell proliferation.

Alteration of gene expression involving signal transduction pathways or transcription regulatory components related to arsenic exposure was also observed in this study. Most of these genes were repressed in study subjects of the high-level arsenic exposure group.

Table 3. Demographic and clinical characteristics of the study subjects as determined by arsenic concentration in whole blood samples, Lanyang Basin, Taiwan.a

| Characteristics | Low (0.00–4.32) | Intermediate (4.64–9.00) | High (9.60–46.5) |
|-----------------|----------------|------------------------|-----------------|
| Total subjects  | 21             | 22                     | 21              |
| Age (years)     | 56.4 ± 6.7     | 58.7 ± 6.7             | 56.5 ± 9.4      |
| Gender (% male) | 33.3           | 54.6                   | 33.3            |
| Body mass index (kg/m²)* | 25.8 ± 3.8 | 25.4 ± 3.8 | 22.9 ± 3.2 |
| Current smoker (%) | 23.8 | 36.4              | 33.3            |
| Serum cholesterol (mmol/L) | 207.3 ± 33.4 | 219.0 ± 31.9 | 203.7 ± 37.8 |
| Serum triglyceride (mmol/L) | 135.2 ± 108.7 | 144.7 ± 87.3 | 117.0 ± 59.3 |

*Values are shown as means ± SD for continuous variables and percentages for dichotomous variables. p < 0.05, derived from an ANOVA F test for the hypothesis that there was no difference among groups.

Table 4. Plasma protein level of four study genes in 64 study subjects as a function of blood arsenic exposure, Lanyang Basin, Taiwan.a

| Protein | Total subjects | Low (0.00–4.32) (number) | Intermediate (4.64–9.00) (number) | High (9.60–46.5) (number) | Correlation coefficient for individual measurements | p Value |
|---------|----------------|--------------------------|----------------------------------|--------------------------|-----------------------------------------------|---------|
| IL1β    | 53             | 0.85 ± 0.51 (18)         | 0.85 ± 0.53 (18)                | 0.74 ± 0.37 (17)         | 0.02                                          | 0.902   |
| IL6     | 51             | 1.7 ± 1.8 (18)           | 2.4 ± 3.1 (20)                  | 1.4 ± 0.9 (13)           | −0.19                                         | 0.190   |
| CCL2/MCP1 | 64           | 4.98 ± 152 (21)         | 530 ± 183 (22)                 | 611 ± 254 (21)          | 0.24                                          | 0.080   |
| CXCL1/GRO1 | 32           | 42.2 ± 19.4 (12)        | 43.8 ± 19.8 (11)               | 47.9 ± 30.4 (8)         | −0.05                                         | 0.766   |

*Protein levels in plasma (pg/mL) are shown as mean ± SD. aInformation from the UniGene database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene). *Subjects with plasma protein level below detection limit by ELISA assay were treated as having missing data.
exposure cell lines have defined the three mitogen-activated protein (MAP) kinases, including extracellular signal-regulated kinase, stress-activated c-Jun N-terminal kinase, and p38/CSBP (CSAID-binding protein) protein kinase, that are involved in the response to lethal levels of arsenic (Cavigelli et al. 1996; Dong 2002; Liu et al. 1996; Ludwik et al. 1998; Theodosiou and Ashworth 2002). In this study, no enhanced activation of MAP kinase pathways was observed in association with arsenic exposure. Relatively low levels of arsenic may have different modes of action, as proposed by Barchowsky (Barchowsky et al. 1999). MAP kinase pathways may not be activated in the study subjects with relatively low-level arsenic exposure, such as those derived from drinking water. In contrast, the transcription factor SPII (spleen focus forming virus proviral integration oncogene), which is essential for the development of hematopoietic system (DeKoter and Singh 2000), is significantly upregulated in lymphocytes from study subjects with high levels of blood arsenic. Deregulation in transcription levels can also be found for genes involved in cell cycle control and DNA replication/repair processes, including induction of menage a cycle control and DNA replication/repair also be found for genes involved in cell development of hematopoietic system (DeKoter and Singh 2000), is significantly upregulated in lymphocytes from study subjects with high levels of blood arsenic. Deregulation in transcription levels can also be found for genes involved in cell cycle control and DNA replication/repair processes, including induction of menage a cycle control and DNA replication/repair processes. However, results of this study showed that arsenic exposure induced expression of cellular defense proteins, such as heme oxygenase 1 (HMOX1) and glutathione peroxidase 4 (GPX4). In many mammalian systems of cell culture, elevation of HMOX1 is a hallmark of increased oxidative stress induced by xenobiotic challenge, including arsenical compounds (Elbirt and Bonkovsky 1999). GPX4 is a component of the glutathione redox system that protects cells against oxidative damage induced by arsenic (Chouchane and Snow 2001; Lee and Ho 1994). Oxidative stress has been proposed as an important mechanism underlying arsenic-induced tissue damage that leads to cell death or gene expression changes (Bernstam and Nriagu 2000; Li et al. 2002; Nakagawa et al. 2002; Snow 1992). In our previous study, enhanced plasma oxidative stress levels associated with arsenic exposure were also observed for this study subjects (Wu et al. 2001). Among the genes of the MMPs family spotted on our array, MMP1, MMP12 (margophage elastase), MMP14, and MMP-19 had enhanced expression in subjects from the high-level arsenic exposure group. It has long been known that increased MMP activity is important in atheroma formation (Bendeck 2002). In addition, increased production of MMPs in activated leukocytes has unfavorable effects for plaque stabilization (Libby 2002; Schonbeck et al. 1997). In arseniasis-endemic area in Taiwan, we observed an increased risk of cerebrovascular disease after long-term arsenic exposure to drinking water (Chen et al. 1996; Chio et al. 1997; Wang et al. 2002). In addition to formation of atheroma, arsenic-induced MMP activity leading to plaque rupture and hemorrhage might play a role in cases of advanced atherosclerosis observed in the study area.

Many inflammatory molecules including CCL2/MCP1 are regulated by nuclear factor kappa-B (NF-kB), which is mediated by oxidative stress (Kokura et al. 2002; Libermann and Baltimore 1990; Shin et al. 2002). Arsenite has been shown to induce oxygen free radicals and thereby increase NF-kB activity in cell culture studies (Barchowsky et al. 1996; Roussel and Barchowsky 2000). Enhanced plasma oxidative stress level associated with arsenic exposure was also observed for the present study subjects (Wu et al. 2001). Arsenic exposure may contribute to atherosclerosis through induction of oxidative stress and redox-sensitive inflammatory gene expression in the vasculature of exposed humans. A promoter analysis for NF-kB binding sites on those upregulated genes identified in this study may provide indicative information on gene regulation by arsenic exposure. Arsenic may alter gene expression as well by influencing promoter activity such as DNA methylation status or sequence variants. Long-term arsenic exposure in experimental animals alters DNA methylation status (Zhao et al. 1997). Whether arsenic exposure causes gene expression induction by a mechanism of demethylation or sequence variants in promoter region of all the affected genes in these study subjects needs additional experimental study.

Several issues need to be addressed. First, the cDNA microarray chip we used in this study was designed to include known genes of potential significance in arsenic toxicity; however, only a defined subset of genes was spotted on the cDNA chip because of difficulty for clone maintenance. It is possible that other gene products also play a role in arsenic-induced atherosclerosis. Second, the decision to pool the total cellular RNA from blood lymphocytes of eight individuals into one group was made to guarantee sufficient mRNA for gene expression profiling as an initial experiment. Because the extent of variability among individuals within one group was not available in this study, reproducibility of comparison between groups for RNA levels may be questioned. However, because the 24 individuals were grouped into various levels of the arsenic dose group with similar age, male/female ratio, and smoker percentage among groups, comparability of the expression profiles obtained as such should be enhanced. This matching strategy should increase the reliability of the microarray

### Table 5. Linear regression analyses on the logarithmic plasma CCL2/MCP1 protein levels for 64 arsenic-exposed residents, Lanyang Basin, Taiwan.

| Variable                        | Coefficient (× 100) | SE (× 100) | p-Value |
|---------------------------------|--------------------|------------|---------|
| **Univariate analysis model**   |                    |            |         |
| Age (1-year increment)          | 0.37               | 0.27       | 0.172   |
| Gender (male vs female)         | 2.51               | 4.14       | 0.547   |
| Blood arsenic (1-µg/L increment)| 0.29               | 0.20       | 0.055   |
| Body mass index, kg/m² (1 unit increment) | -0.86              | 0.53       | 0.112   |
| Current smoker (yes vs no)      | 4.27               | 4.37       | 0.332   |
| Serum cholesterol (one mmol/L increment) | 0.03               | 0.06       | 0.666   |
| Serum triglyceride (one mmol/L increment) | 0.02               | 0.02       | 0.357   |
| **Multivariate analysis model** |                    |            |         |
| Age (1-year increment)          | 0.33               | 0.26       | 0.211   |
| Gender (male vs female)         | 2.97               | 4.10       | 0.472   |
| Blood arsenic (1-µg/L increment)| 0.41               | 0.20       | 0.048   |

*Plasma CCL2/MCP1 protein level (µg/mL) in logarithm scale was detected by ELISA assay. *SE: standard error of the coefficient. *Probability derived from a Wald’s chi-square test for the hypothesis that coefficient = 0.
data. In addition, an alternate measure of gene expression, ELISA assay, was used to confirm the initial gene array analysis of genes, which adds substantially to the reproducibility of this study. Third, as only one chip was spotted for each dose level in this study and the variability across chips was not obtained, a standard curve using serial-diluted GAPDH clones was generated to control the variation between hybridization experiments, including variability from chip to chip. Furthermore, the variance in expression of the housekeeping genes was used to measure the significance of gene expression changes for study genes. As the variability in the expression of housekeeping genes probably overestimated the experimental variability in measuring differential expression, the resulting comparison under study should have been underestimated. Finally, the number of study subjects may not be large enough for most of the genes under study to draw a definitive conclusion on the association between expression level and arsenic exposure gradient. A larger sample size will be needed, especially for studies using diverse human population and gene markers of great experimental variability, to evaluate the effect of environmental factors on the gene expression profile.

In conclusion, this exploratory study demonstrates the potential of cDNA microarray as a method to identify candidate genes associated with arsenic exposure, an atherogenic stimulus, and provides novel investigational targets including genes involved in inflammation and immune response. Although PBL is not representative of all inflammatory cells in atherosclerotic lesion areas, the result of a dose-dependent elevation of plasma CCL2/MCP1 protein levels in the study subjects may yield insight into the response to atherogenic stimulus after long-term arsenic exposure. Further research that extends the sample size of this study as well as exploration of gene expression profile of other inflammatory cytokines and growth factors in arsenic-exposed population are needed to define the dose-response relationship between the exposure and inflammatory mediators at the population level. Multidisciplinary studies such as molecular epidemiologic investigations are also needed to elucidate the role of arsenic-associated inflammation in the induction of atherosclerosis.

References

Bagla P, Kaiser J. 1996. India's spreading health crisis draws global arsenic experts. Science 274:174–175.

Barchowsky A, Dukan EJ, Treadwell MD, Wetterhahn KE. 1996. Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Free Radiol Bio Med 21:783–790.

Barchowsky A, Roussel RR, Klei LR, James PE, Ganju N, Smith KR, et al. 1999. Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways. Toxicol Appl Pharmacol 159:65–75.

Bates MN, Smith AH, Hopenhayn-Rich C. 1992. Arsenic ingestion and internal cancers: a review. Am J Epidemiol 135:462–476.

Bendele MP. 2002. Matrix metallocortinases: are they antithrombogenic but proprotease? Circ Res 90:836–837.

Bernstam L, Nriagu J. 2000. Molecular aspects of arsenic stress. J Toxicol Environ Health B Crit Rev 3:293–322.

Cavigelli M, Li WW, Lin A, Su B, Yoshioha K, Karin M. 1996. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. Embo J 15:6269–6279.

Chen CJ, Chiou HY, Chiang MH, Lin LJ, Tai TY. 1996. Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler Thromb Vasc Biol 16:504–510.

Chen CJ, Hsu LI, Tseng CH. 1999. Emergent epidemics of arsenia in Asia. In: Arsenic Exposure and Health Effects (Chappell WR, Abernathy CD, Calderon RL, eds). Amsterdam: Elsevier. 113–121.

Chen, CJ, Hsueh YM, Lai MS, Shyu MP, Chen SY, Wu MM, et al. 1995. Increased prevalence of hyper tension and long-term arsenic exposure. Hypertension 25:53–60.

Chen CJ, Wu MM, Lee SS, Wang JD, Cheng SH, Wu HY. 1998. Thrombocytopenia and carboxycenicogenic of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis 8:452–460.

Chen H, Liu J, Merrick BA, Waalkes MP. 2001. Genetic events associated with arsenic-induced malignant transformation: applications of cDNA microarray technology. Mol Carcinog 30:79–87.

Chen, LJ, Wu R, Yang FC, Huang JY, Shyr YP, Han MH, et al. 1998. Profiling expression patterns and isolating differentially expressed genes by cDNA microarray system with colorimetry detection. Genomics 51:313–324.

Chen HY, Huang WI, Su CL, Chang SF, Hsu HY, Chen CJ. 1997. Dose-response relationship between prevalence of cardiovascular disease and ingested inorganic arsenic. Stroke 28:1717–1723.

Chouhan S, Snow ET. 2001. In vitro effect of arseni compounds on glutathione-related enzymes. Chem Res Toxicol 14:517–522.

DeKoter RP, Singh H. 2000. Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science 288:1439–1441.

Devitt A, Moffatt DD, Raykundalia C, Capra JD, Simmons DL, Gregory CD. 1998. Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 392:505–509.

Dong Z, 2002. The molecular mechanisms of arsenic-induced cell transformation and apoptosis. Environ Health Perspect 110(suppl 5):757–759.

Elbirt KK, Bonkovsky HL. 1999. Heme oxygenase: recent advances in understanding its regulation and role. Proc Assoc Am Physicians 111:438–447.

Engel RR, Hopenhayn-Rich C, Racevee O, Smith AH. 1994. Vascular effects of chronic arsenic exposure: a review. Epidemiol Rev 16:184–209.

Engelse MA, Neele JM, van Achterberg TA, van Aken BE, van Schaik RH, Pannekoek H, et al. 1989. Human activin-A is expressed in the atherosclerotic lesion and promotes the contractile phenotype of smooth muscle cells. Circ Res 85:931–939.

Everett AD, Stoops T, McNama CA. 2001. Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem 276:37564–37568.

Germolec DR, Spalding J, Boorman GA, Wilmer JL, Yoshida T, Simeonova PP, et al. 1997. Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors. Mutat Res 386:209–218.

Germolec DR, Spalding J, Yu HS, Chen GS, Simeonova PP, Humble MC, et al. 1998. Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am J Pathol 153:1775–1786.

Hampe A, Shamooin BM, Gobet M, Sherr CJ, Galibert F. 1999. Nucleotide sequence and structural organization of the human FMS proto-oncogene. Oncogene 49:9–17.

Hsueh YM, Wu WI, Huang YL, Chiou HY, Tseng CH, Chen CJ. 1998. Low serum carotene level and increased risk of ischemic heart disease related to long-term arsenic exposure. Atherosclerosis 141:249–257.

Huo Y, Weber C, Forlow SB, Sperandio M, Thatte J, Mack M, et al. 2001. The chemokine KC, but not monocyte chemotactrant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J Clin Invest 108:1307–1314.

Kitchin, KT. 2001. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol 172:249–261.

Klouche M, Rose-John S, Bhakdi S. 2000. Enzymatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation. Circulation 101:1799–1805.

Kokura S, Yoshida N, Yoshikawa T. 2002. Anoxia/reoxygenation-induced leukocyte-endothelial cell interactions. Free Radiol Bio Med 31:427–432.

Kumar S. 1997. Widescale arsenic poisoning found in South Asia. Lancet 349:1378.

Lee TC, Ho IC. 1994. Differential cytotoxic effects of arsenic on human and animal cells. Environ Health Perspect 102(suppl 1):101–105.

Li M, Cai JF, Choi JF. 2002. Arsenic induces oxidative stress and activates stress gene expression in cultured lung epithelial cells. J Cell Biochem 87:29–38.

Libby P. 2002. Inflammation in atherosclerosis. Nature 420:868–874.

Libby P, Ridker PM, Maseri A. 2002. Inflammation and atherosclerosis. Circulation 105:1135–1143.

Liebermann TA, Baltimore D. 1990. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 10:2327–2334.

Liu Y, Goytan KS, Gorospe M, Xu G, Lee JC, Holbrook NJ. 1996. Differential activation of ERK, JNK/SAPK and p38/CSBP/RK map kinase family members during the cellular response to arsenite. Free Radiol Bio Med 21:771–781.

Lu T, Liu J, LeClyuse EL, Zhou YS, Cheng ML, Waalkes MP. 2001. Application of cDNA microarray to the study of arsenic-induced liver diseases in the population of Guizhou, China. Toxicol Sci 58:195–192.

Ludwig S, Hoffmeyer A, Goeberler M, Kilian K, Engel RR, Hopenhayn-Rich C, Racevee O, Smith AH. 1994. Vascular effects of chronic arsenic exposure: a review. Epidemiol Rev 16:184–209.
Hafner H, Neufeld B, et al. 1998. The stress inducer induces mitogen-activated protein kinases extracellular signal-regulated kinases 1 and 2 via a MAPK kinase 6-dependent pathway. J Biol Chem 273:1917–1922.

Morrison TB, Weis JJ, Wittwer CT. 1998. Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques 24:954–958, 960, 962.

Nakagawa Y, Akao Y, Morikawa H, Hirata I, Katsu K, Naoe T, et al. 2002. Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci 70:2253–2269.

Nordstrom K. 2002. Worldwide occurrences of arsenic in ground water. Science 296:2143–2144.

Rosenfeld ME. 2002. Leukocyte recruitment into developing atherosclerotic lesions: the complex interaction between multiple molecules keeps getting more complex. Arterioscler Thromb Vasc Biol 22:1293–1298.

Tseng WP. 1977. Effects and dose-response relationships of skin cancer and blackfoot disease with arsenic. Environ Health Perspect 19:108–119.

Tseng CH, Chong CK, Chen CJ, Lin BJ, Tai TY. 1995. Abnormal peripheral microcirculation in seemingly normal subjects living in blackfoot-disease-hyperendemic villages in Taiwan. Int J Microcirc Clin Exp 15:21–27.

Tseng CH, Chong CK, Chen CJ, Tai TY. 1996. Dose-response relationship between peripheral vascular disease and ingested inorganic arsenic among residents in blackfoot disease endemic villages in Taiwan. Atherosclerosis 120:125–133.

———. 1997. Lipid profile and peripheral vascular disease in arseniasis-hyperendemic villages in Taiwan. Angiology 48:321–335.

———. 1997. Rapid cycle DNA amplification. Biotechniques 22:361–363.

———. 1997. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 22:130–131, 134–138.

Wolpe SD, Sherry B, Juers D, Davatelas G, Yurt RW, Cerami A. 1989. Identification and characterization of macrophage inflammatory protein 2. Proc Natl Acad Sci USA 86:612–616.

Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MM, Chiou HY, Wang TW, Hsueh YM, Wang IH, Wolpe SD, Sherry B, Rockson SG. 2002. The role of chemokines in human cardiovascular pathophysiology: enhanced biological insights. Atherosclerosis 160:91–102.

Snow ET. 1992. Metal carcinogenesis: mechanistic implications. Pharmacol Ther 53:31–65.

Swart GW. 2002. Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol 81:313–321.

Theodosiou A, Ashworth A. 2002. Differential effects of stress stimuli on a JNK-inactivating phosphatase. Oncogene 21:2387–2397.

Thornton I, Farago M. 1997. The geochemistry of arsenic. London: Chapman & Hall.

Toxicological Profile for Arsenic. Washington, DC:U.S. Public Health Service.

Venkataraman M, Westerman MP. 1986. Susceptibility of human T cells, T-cell subsets, and B cells to cryopreservation. Cryobiology 23:193–208.

Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, et al. 2002. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105:1890–1896.

Wang, CH, Jeng JS, Yip PK, Chen CL, Hsu LI, Hsueh YM, et al. 2002. Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation 105:1804–1809.

Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP. 1997. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 22:130–131, 134–138.

Wolpe SD, Sherry B, Juers D, Davatelas G, Yurt RW, Cerami A. 1989. Identification and characterization of macrophage inflammatory protein 2. Proc Natl Acad Sci USA 86:612–616.